AU2006322073A1 - dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants - Google Patents

dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants Download PDF

Info

Publication number
AU2006322073A1
AU2006322073A1 AU2006322073A AU2006322073A AU2006322073A1 AU 2006322073 A1 AU2006322073 A1 AU 2006322073A1 AU 2006322073 A AU2006322073 A AU 2006322073A AU 2006322073 A AU2006322073 A AU 2006322073A AU 2006322073 A1 AU2006322073 A1 AU 2006322073A1
Authority
AU
Australia
Prior art keywords
vaccine
dsrna
influenza
immuno
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006322073A
Other languages
English (en)
Inventor
William A. Carter
David Strayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIM Immunotech Inc
Original Assignee
Hemispherx Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemispherx Biopharma Inc filed Critical Hemispherx Biopharma Inc
Publication of AU2006322073A1 publication Critical patent/AU2006322073A1/en
Assigned to HEMISPHERX BIOPHARMA, INC. reassignment HEMISPHERX BIOPHARMA, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: HEMISPHERX BIOPHARMA
Priority to AU2013206335A priority Critical patent/AU2013206335B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2006322073A 2005-12-07 2006-12-06 dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants Abandoned AU2006322073A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013206335A AU2013206335B2 (en) 2005-12-07 2013-06-14 dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74290605P 2005-12-07 2005-12-07
US60/742,906 2005-12-07
US75289805P 2005-12-23 2005-12-23
US60/752,898 2005-12-23
US79323906P 2006-04-20 2006-04-20
US60/793,239 2006-04-20
PCT/US2006/046356 WO2007067517A2 (en) 2005-12-07 2006-12-06 Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013206335A Division AU2013206335B2 (en) 2005-12-07 2013-06-14 dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants

Publications (1)

Publication Number Publication Date
AU2006322073A1 true AU2006322073A1 (en) 2007-06-14

Family

ID=38123418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006322073A Abandoned AU2006322073A1 (en) 2005-12-07 2006-12-06 dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants

Country Status (6)

Country Link
US (3) US7943147B2 (https=)
EP (1) EP1957101A4 (https=)
JP (2) JP2009518410A (https=)
AU (1) AU2006322073A1 (https=)
CA (1) CA2632516C (https=)
WO (1) WO2007067517A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009337A2 (en) * 2003-05-16 2005-02-03 Hemispherx Biopharma Treating severe acute respiratory syndrome
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
AU2006322073A1 (en) * 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
CA2690641A1 (en) * 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
JP2011525169A (ja) * 2008-02-15 2011-09-15 へミスフェリックス・バイオファーマ，インコーポレーテッド Ｔｏｌｌ様受容体３の選択的アゴニスト
US20110110979A1 (en) * 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
ES2588183T3 (es) 2009-03-31 2016-10-31 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
JP2022543735A (ja) 2019-07-02 2022-10-14 エヌエー ヴァクシン インスティテュート 新規のリボ核酸、及びそれを基にする薬剤学的組成物
WO2021040439A1 (ko) * 2019-08-28 2021-03-04 주식회사 엔에이백신연구소 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
RU2390351C2 (ru) 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
AU2006322073A1 (en) * 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
EP2134172A4 (en) 2007-03-05 2011-06-01 Univ Utah State RESTRICTIVE AGONIST OF THE TOLL LIKE RECEPTOR 3

Also Published As

Publication number Publication date
EP1957101A4 (en) 2010-04-07
US20110223198A1 (en) 2011-09-15
US7943147B2 (en) 2011-05-17
JP2013075920A (ja) 2013-04-25
US20150064216A1 (en) 2015-03-05
WO2007067517A2 (en) 2007-06-14
CA2632516A1 (en) 2007-06-14
JP2009518410A (ja) 2009-05-07
WO2007067517A3 (en) 2008-01-31
EP1957101A2 (en) 2008-08-20
CA2632516C (en) 2018-05-15
US20070224219A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
EP0528859B1 (en) Oral vaccine comprising antigen surface-associated with red blood cells
JP6308500B2 (ja) 強化された免疫賦活化剤
TWI421091B (zh) 包含以聚肌苷酸-聚胞苷酸為主之佐劑的黏膜免疫物質
Chen et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization
JP2003523310A (ja) 新規インフルエンザウイルスワクチン組成物
Kumar et al. Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus
EP3403671B1 (en) Vaccine containing immobilized virus particles
Jarouliya et al. Developing Vaccine Against COVID-19 and Immune Response
Hua et al. Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice
Hoover et al. N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection
CN114746114B (zh) 以新型核酸为基础的流感疫苗组合物
CN102813920A (zh) 一种疫苗佐剂
AU2013206335B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
TWI764111B (zh) 調節黏膜免疫原性之方法
US20260061046A1 (en) Combination Vaccine For Prevention Of Influenza And Coronavirus Infections
Yuen et al. Flu-based and PD1-based vaccines for SARS-CoV-2: abridged secondary publication
Duggal et al. COVID-19 VACCINES; A COMPARATIVE ANALYSIS OF THEIR DISTINGUISHING CHARACTERISTICS EFFICACY, EFFECTIVENESS AND ADVERSE EFFECTS
CN101410133A (zh) 作为流感病毒疫苗佐剂或免疫刺激物的dsRNA
WO2025084106A1 (ja) 経鼻投与による細胞性免疫の誘導方法
Morgan et al. Vaccine adjuvants for infectious disease in the clinic
CN117462667A (zh) 一种复合佐剂及其在疫苗制备中的应用
CN106163554A (zh) 一种包含pika佐剂的狂犬病组合物
Falkeborn et al. Comparison of the mucosal adjuvant Endocine™ with two well-known adjuvants: Cholera toxin and alum
WO2014176530A1 (en) Vaccination methods

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted